The gain or loss of more than 5% bodyweight within a 2-year period is associated with an increased risk for major adverse cardiovascular events in people with type 2 diabetes, say researchers.
The virtual CHIEF-HF trial has demonstrated a significant positive effect of canagliflozin on heart failure symptoms without the need for in-person clinic visits, the investigators report in Nature Medicine.